fda compounding semaglutide warning letters october 2025 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA warns against compounded GLP-1

For patients seeking additional weight loss, microdosing is generally less effective than standard therapeutic dosing

The bigger issue remains that they cannot regulate the growing number of non-healthcare practitioners now flooding the market with B12 services

There is no shortcut to safe and lasting weight loss

Such tailored intervals would significantly enhance the clinical utility of laboratory indicators [11, 12]

However, this slower transit can be detrimental to your gut health and your microbiome (the community of microorganisms that live in and aid your digestive tract.) Decades of research have shown a significant link between slowed motility and harmful microbial overgrowths